Moberg Pharma and Cadila Pharmaceuticals enters agreement for late-stage...
(Source: Moberg Pharma AB) Under the Development and License Agreement, Cadila Pharmaceuticals will conduct a phase III program in India and is granted an exclusive license to commercialize BUPI in...
View ArticleCumberland Pharmaceuticals Announces New Program To Develop Vasculan™ For...
(Source: Cumberland Pharmaceuticals Inc) NASHVILLE, Tenn., April 27, 2016 /PRNewswire/ -- Cumberland Pharmaceuticals Inc. (NASDAQ: CPIX), a specialty pharmaceutical company focused on the development...
View ArticleQ1-2016 Interim results (Serodus ASA)
(Source: Serodus ASA) Oslo, 27. April 2016. Serodus ASA (OAX:SER) announces its results for the first quarter 2016. Highlights include: SER150 Diabetic Nephropathy Follow-up period after Cohort 1 of...
View ArticleSerodus ASA (OAX:SER) announces its results for the fourth quarter 2014....
(Source: Serodus ASA) Highlights include: SER150 Manufacture of SER150 drug capsules follows the time schedule. A feasibility study has identified the clinical centres to be involved in Phase IIa...
View ArticleAnnual Report 2015 (Serodus ASA)
(Source: Serodus ASA) The Board of Directors of Serodus ASA has today approved the Annual Report 2015 including complete 2015 Annual Accounts with notes. The report...
View ArticleNotice of Annual General Meeting 24 May 2016 (Serodus ASA)
(Source: Serodus ASA) Oslo, (03.05.2016) The annual general meeting of Serodus ASA will be held on 24 May 2016 at 15:00 at Forskningsparken, Gaustadalleen 21, 0349 Oslo. Meetingroom Hagen 1....
View ArticleSerodus ASA: Update of financial calendar (Serodus ASA)
(Source: Serodus ASA) Oslo 20 October 2014: Serodus ASA (Oslo Axess: SER), has updated the financial calendar. The presentation of Q3 Results 2014 will be held 23. October 2014, a change from...
View ArticleProvisional patent application filed for the Orphan Diseases of Pulmonary...
(Source: Serodus ASA) "We are pleased to introduce a new indication for one of our drug candidates. SER100 will now also be developed in Pulmonary Hypertension and the project will be named as SER200"...
View ArticleSERODUS ASA: STRENGTHENING OF MANAGEMENT TEAM (Serodus ASA)
(Source: Serodus ASA) Jürgen Langhärig holds a PhD in Industrial Microbiology from the University of Tübingen, Germany and an MBA from St. Gallen University, Switzerland. Jürgen Langhärig brings more...
View ArticleContemplated rights issue (Serodus ASA)
(Source: Serodus ASA) Oslo, 8. July 2015; Reference is made to Serodus ASA ('Serodus' or the 'Company') quarterly report published on 24 April 2015 regarding the financing process. After evaluation of...
View ArticleSerodus granted patent in Japan for product candidate within acute myocardial...
(Source: Serodus ASA) The patent covers methods for treating various diseases caused by inflammation. This patent has already been issued to Serodus in United States, New Zealand and Russia and is...
View ArticleProvisional patent application filed in order to strengthen the position of...
(Source: Serodus ASA) Oslo, October 28, 2015: Serodus ASA (Oslo Axess: SER), a Scandinavian biotech company with focus on cardiovascular and metabolic diseases, has filed a new provisional patent for...
View ArticleSerodus announces invitation to collaborate with National Kidney Foundation -...
(Source: Serodus ASA) Serodus today announced that the National Kidney Foundation (US) has invited Serodus to join a collaboration between the Food and Drug Administration (FDA), the European Medical...
View ArticleSerodus to present at BioEquity Europe on 11 May 2016 (Serodus ASA)
(Source: Serodus ASA) Serodus ASA, Oslo, Norway, 4th of May 2016 (Oslo Axess: SER), a biotechnology company focusing new therapeutic treatment within diabetes and cardiovascular diseases announces that...
View ArticleSerodus summary from capital markets day 15 September 2014 (Serodus ASA)
(Source: Serodus ASA) Oslo, 15 September 2014: With reference to the previously announced Capital Markets Day the lectures and presentations are available on...
View ArticleSER130 for reducing scar size in Acute Myocardial Infarction Patent,...
(Source: Serodus ASA) Oslo, April 29, 2015: Serodus ASA (Oslo Axess: SER), today announced that State Intellectual Property Office of the People's Republic of China (SIPO) has granted to Serodus patent...
View ArticleNovel article on SER140 in diabetes made publicly available in Journal of...
(Source: Serodus ASA) Oslo, February 5, 2016: Serodus (Oslo Axess: SER), are pleased to inform that an article on SER140 has been published in the Journal of Diabetes Research under the title ' The...
View ArticleInvitation to a presentation of Q4 2015 results (Serodus ASA)
(Source: Serodus ASA) Oslo - 12. February 2016 - Serodus ASA (Oslo Axess, SER) will present the Q4 results 2015 at Hotel Continental, Stortingsgaten 24/26, Oslo, Wednesday 17 February 2016...
View ArticleSerodus enter into Market Making agreement (Serodus ASA)
(Source: Serodus ASA) Oslo, 30. March 2016. Serodus ASA (OAX:SER) Serodus ASA has entered into a market making agreement with Norne Securities AS with effect from 30 March 2016. The purpose...
View ArticleInvitation to a presentation of Q3 2015 results (Serodus ASA)
(Source: Serodus ASA) Oslo - 21. October 2015 - Serodus ASA (Oslo Axess, SER) will present the Q3 results 2015 at Hotel Continental, Stortingsgaten 24/26, Oslo, Tuesday 27 October 2015 at...
View Article
